Teva’s CEO Kåre Schultz has had his hands full since taking the helm in 2017. Now, he needs to locate his next finance chief. More: Teva scouts new CFO as McClellan steps down for personal reasons Source: fierce
read moreAllergan has confirmed it will hive off two drugs to help AbbVie’s $63 billion takeover pass U.S. antitrust scrutiny. But recent regulatory decisions—and indecision—on pharma deals has analysts worried whether those selloffs would be enough. More: Is Allergan unloading 2
read moreThe drug is recommended provided that Herceptin (trastuzumab) is the only HER2-directed adjuvant treatment people have had. More: New early breast cancer option recommended by NICE Source: News
read moreThe study will evaluate the drug in menopause related vasomotor symptoms, such as hot flashes and night sweats. More: First patient dosed in Astellas’ late-stage menopause trial Source: News
read moreFatigue is one of the most common side effects of cancer and its treatment, with 70-80% of patients affected. More: NHS approves app for cancer related fatigue Source: News
read moreThe treatment is the only PARP inhibitor with positive Phase III results in four different cancer types – ovarian, breast, pancreatic and prostate. More: Trial success for Lynparza in prostate cancer Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals